NextCell Pharma

Hong Kong is rapidly positioning itself as an international hub for regulatory innovation, clinical research, and capital markets, while serving as a strategic and operational access point to China and the GBA - a region of 87 million inhabitants and one of the world's fastest-growing life science ecosystems.

"Hong Kong represents a highly interesting bridge into China, both from a regulatory and commercial perspective. NextCell is actively exploring the possibility of establishing a presence in the region as a future pathway for clinical development and partnerships in the Chinese market," says Mathias Svahn, CEO of NextCell Pharma.

The delegation includes meetings with Hong Kong's Innovation, Technology and Industry Bureau (ITIB), Invest Hong Kong, Hong Kong Science & Technology Parks (HKSTP), and Hong Kong Exchanges and Clearing (HKEX), with a focus on regulatory opportunities, clinical collaborations, and investor relations.